Development and Translation of Hyperpolarized C-13 Prostate Cancer MRI Methods

超极化 C-13 前列腺癌 MRI 方法的开发和转化

• 批准号: 10588591
• 负责人: Jeremy William Gordon
• 金额: $ 3.82万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10588591
• 关键词: 3-Dimensional; Acceleration; Address; Adoption; Biomedical Engineering; Biopsy; Bone Diseases; Cancer Patient; Citric Acid Cycle; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Computer software; Data; Development; Disease; Disseminated Malignant Neoplasm; Evaluation; Extramural Activities; Future; Gland; Goals; Gold; Guidelines; Histopathology; Human; Image; Imaging Techniques; Injections; Interdisciplinary Study; Intervention; Investigation; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Measurement; Measures; Metabolic; Metabolism; Metastatic Neoplasm to Lymph Nodes; Metastatic Prostate Cancer; Methods; Monitor; Pathologic; Patient Care; Patients; Pelvis; Pharmacologic Substance; Pharmacy facility; Phase; Physiologic pulse; Positron-Emission Tomography; Predisposition; Production; Prostatectomy; Pyruvate; Pyruvate Metabolism Pathway; Reproducibility; Research; Research Personnel; Resistance; Resolution; Scientist; Site; Sterility; Structure; Techniques; Technology; Testing; Therapeutic Intervention; Time; Translating; Translations; United States National Institutes of Health; Variant; Visceral; anticancer research; base; cost effective; design; hip bone; imaging approach; imaging modality; improved; individual patient; interest; lymph nodes; metabolic imaging; molecular imaging; multi-site trial; multidisciplinary; new technology; novel; novel strategies; novel therapeutics; open source; pre-clinical; research study; response; stable isotope; success; tool; treatment response

Project Summary/Abstract This Bioengineering Research Partnership has been designed to develop new techniques to perform primary and especially metastatic prostate cancer patient HP 13C MRI exams with the goal of creating a robust, reliable exam with 2-fold higher SNR, 5-fold higher spatial coverage, and new metabolic information from C-2 pyruvate to benefit prostate cancer research, clinical trials evaluating new treatments, and ultimately patient care. Preliminary studies have demonstrated the ability of dynamic HP 13C MR to detect upregulated LDH-catalyzed pyruvate to lactate conversion in aggressive prostate cancers and also to measure a dramatic reduction following successful therapy. While “proof-of-principle” has been shown in these initial studies, new bioengineering developments, hardware, and software are required to create a robust, cost-effective HP 13C MRI exam to fulfill clinical unmet needs. The current techniques are not robust, well-characterized tools ready to be widely applied. This BRP, with its specialized multidisciplinary research team, is designed to accomplish the required bioengineering developments and patient clinical research needed to refine, test and disseminate these new techniques & hardware following the NIH guidelines for scientific rigor, transparency and reproducibility. Specifically, we aim to: 1) Improve HP Pharmacy Methods for Producing Sterile HP 13C-pyruvate; 2) Develop New Robust HP 13C MR Technology for Primary Prostate Cancer; and 3) Specific Technical Developments for Metastatic Prostate Cancer Exam. New robust acquisition and analysis techniques will be developed and tested in pre-prostatectomy patients with the correlation of kPL & kPG conversion rate constants to step-section histopathology as the gold standard. Also the new methods will be applied in studies of patients with metastases to lymph nodes and pelvic bone to investigate their ability to detect therapy response/resistance for individual patients and future clinical trials of emerging pharmaceutical strategies. While focused on prostate cancer, the proposed BRP aims to develop new HP 13C metabolic imaging techniques that will ultimately benefit the clinical management of a wide variety of diseases. All techniques, hardware designs, pharmacy methods, open-source software, and anonymized patient data from this BRP project will be disseminated to all interested sites continuing this BRP’s active dissemination methods to over 20 sites thus far in order to accelerate the tempo and improve the clinical impact of this powerful molecular imaging approach.

项目摘要/摘要 这种生物工程研究合作伙伴关系旨在开发新技术以执行主要 特别是转移性前列腺癌患者HP 13C MRI检查，目的是创建强大，可靠的 考试高2倍，SNR高5倍，空间覆盖率高5倍，以及来自C-2丙酮酸的新代谢信息 为了使前列腺癌研究受益，临床试验评估了新治疗，并最终将患者护理。 初步研究表明，动态HP 13C MR检测到更新的LDH催化的能力 丙酮酸将侵略性前列腺癌的转化损伤，并测量显着降低 成功的治疗。尽管在这些初步研究中已经显示了“原理证明”，但新的生物工程 需要开发，硬件和软件来创建强大的，具有成本效益的HP 13C MRI考试以履行 临床未满足的需求。当前的技术不是可靠的，可以广泛应用的特征良好的工具。 这个BRP及其专门的多学科研究团队，旨在完成所需的 生物工程发展和患者临床研究需要完善，测试和传播这些新的 遵循NIH的科学严谨性，透明度和可重复性的技术和硬件。 具体而言，我们的目标是：1）改善HP药房生产无菌HP 13C-丙酮酸的方法； 2）发展 新的强大HP 13C MR技术用于原发性前列腺癌； 3）特定的技术发展 转移性前列腺癌检查。将开发和测试新的强大的获取和分析技术 在遗产前切除术患者中，KPL和KPG转化率常数与步长的相关性 组织病理学作为黄金标准。另外，新方法将应用于转移患者的研究 淋巴结和骨盆骨，研究其检测个体治疗反应/抗药性的能力 患者和未来的新兴药物策略临床试验。虽然专注于前列腺癌，但 拟议的BRP旨在开发新的HP 13C代谢成像技术，最终将受益于临床 管理多种疾病。所有技术，硬件设计，药房方法，开源 该BRP项目的软件和匿名患者数据将被传播到所有有趣的网站 迄今为止，继续使用该BRP的主动传播方法到20多个站点以加速节奏 并改善这种强大的分子成像方法的临床影响。